[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chirec\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100634884","ablative-therapy-of-oligometastatic-tumor-after-response-to-conventional-first-line-treatment-100634884",false,"NCT07545486","Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment","ATOM-1st","Inclusion Criteria:\n\n1. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG).\n2. Histologically diagnosis of one of these tumour types:\n\n   1. Hormone receptor positive, HER2 negative breast cancer\n   2. Triple negative breast cancer\n   3. HER2+ breast cancer\n   4. Non small cell lung cancer without oncogenic addiction\n   5. Head and Neck squamous cell carcinoma without recurrence in the radiation field\n   6. Gastric adenocarcinoma\n   7. Esophageal cancer (adenocarcinoma or epidermoid carcinoma)\n   8. Recurrent pancreatic cancer without local recurrence\n   9. Anal cancer\n   10. Bladder cancer\n   11. Clear cells renal cell carcinoma\n   12. Prostate cancer sensitive to castration\n   13. Adenocarcinoma endometrial cancer\n   14. Epidermoid carcinoma or adenocarcinoma of the cervix\n   15. Colorectal cancer\n   16. Recurrent Soft Tissue Sarcoma\n   17. Melanoma\n3. Patient with a decision by the local team to give OST and effective administration of OST. OST is defined as the most efficient choice in terms of survival in first line of advanced disease according to ESMO or other international guidelines. In case of multiple choice as first line, if no data provided direct evidence of superiority from one or the other options, there are all considered as OST. If the patient received a less efficient treatment because of his comorbidity or frailty, the eligible criteria won't be fulfilled.\n4. Have non-progressive disease after 3 to 6 months of treatment, and less than 6 weeks before presentation to the multidisciplinary team\n\n   1. Patients with complete response and no target lesion are excluded.\n   2. Patients with bone metastasis with remaining bone condensation or scare from tumoral activity may be eligible depending on metabolic activity of the lesion or local multidisciplinary committee decision concerning the risk of residual disease.\n5. After 3 to 6 months of treatment, and less than 6 weeks before start of LAT, patient must have an oligometastatic disease defined as all lesions (including primitive lesion) amenable to local ablative treatment according to local investigator team and respective local committee.\n\nExclusion Criteria:\n\n1. Patients who already received systemic antitumoral treatment in the advanced setting (including chemotherapy, immunotherapy, targeted therapy, …)\n2. Patients without OST administration\n3. Patients that have progressing lesion at any time point before decision of LAT by the expert committee\n4. Has a known recent history of other invasive tumour, excepted if local investigator may provide histologically data that all active lesions targeted are from the same cancer primitive.\n5. Radiotherapy or other LAT to any metastatic site before the start of OST.\n6. Exclusion criteria specific for France: Vulnerable persons according to the article L.1121-6 of the public health law (CSP), adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP","ALL","18 Years",{"count":19,"type":20},1235,"ESTIMATED","OBSERVATIONAL","Advancements in systemic antineoplastic therapies have led to improved overall survival rates for many solid tumors. However, metastatic disease remains a significant challenge and remains the leading cause of mortality for these patients. Additionally, there is a high attrition rate after first-line standard treatment across various tumor types, with studies indicating that 20-70% of patients may be unable to undergo second-line therapy, depending on the tumor type.\n\nThis highlights an urgent need to enhance outcomes from the first line of treatment. Although first-line therapy often represents the best available option, most patients experience relapse and disease progression despite an initial tumor response. This is attributed to both intrinsic and acquired resistance arising from the heterogeneity of primary tumors and metastases. To address this issue, metastasis-directed therapy (MDT) has been explored as a way to reduce tumor burden and mitigate the risk of resistance due to therapeutic selective pressure.\n\nMDT offers a promising opportunity to improve first-line treatment outcomes, but more precise patient selection criteria are needed to maximize therapeutic benefit and minimize the potential toxicity of ablative therapies. Indeed, despites its efficacy, fatal complication may occur so do grade 3 to 4 toxicities. Toxicity depends of the local ablative therapy (LAT) planned but as it will never be none, oncologists have to propose invasive treatment to patient that may benefit the most.\n\nBased on the published data, the investigators propose a pragmatic, selective approach centered on sensitivity to systemic therapy. The investigators aim to evaluate the benefit of local ablative therapy (LAT) in patients who demonstrate non-progressive disease after three months of first-line standard of care. Given the importance of this question across cancer subtypes, the investigators will employ a prospective database to enroll patients with various solid tumor type, excluding the ones for which the impact of LAT has already been explored or may be difficult to achieve. Outcomes of this strategy will be evaluated compared to outcomes from pivotal studies defining optimal standard first line therapy (OST) .\n\nSeveral analyses will be performed to better characterize the population for whom a multimodal approach may significantly improve their survival. The first one will aim to compare the median duration of response (mDOR) of the population treated with LAT compared to the mDOR reported by the pivotal study(ies) of each OST.\n\nThis study will serve as a proof of concept, supporting chemosensitivity as a viable selection factor for multimodal treatment in a broad range of cancer types.\n\nPrimary objective:\n\nImprovement of the duration of response (DOR) after completion of LAT compared to DOR reported in pivotal study that evaluated first line OST.\n\nSecondary objectives:\n\n* Evaluation of the safety of the addition of LAT.\n* Evaluation of overall progression free survival (PFS) and PFS at 1 year.\n* Evaluation of overall survival from OST start and from the time of LAT completion.\n* Documentation of acceptance and compliance to LAT decision by the institutional expert committee",[24],"Solid Tumor","NOT_YET_RECRUITING","2026-04-21",{"date":28,"type":29},"2026-04-22","ACTUAL",{"date":31,"type":20},"2026-06-01",{"date":33,"type":20},"2036-06-01",{"name":35,"class":36},"Chirec","OTHER",12,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":62},"100618537","phase-4-study-the-anti-inflammatory-effect-of-tranexamic-acid-when-used-in-anterior-cruciate-ligament-reconstruction-100618537","NCT07332910","Study the Anti-inflammatory Effect of Tranexamic Acid When Used in Anterior Cruciate Ligament Reconstruction.","Tranexaminc Acid : Single Dose vs Placebo to Modulate Postoperative Inflammation After ACL Reconstruction : A Prospective, Randomized, Double-blind Trial","TXA","Inclusion Criteria\n\n* Adults aged 18 years or older.\n* Male or female patients scheduled for primary anterior cruciate ligament (ACL) reconstruction.\n* Surgery performed under spinal anesthesia, combined with a postoperative adductor canal block for analgesia.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Procedure performed by a single, standardized surgical team.\n* Ability to provide written informed consent.\n\nExclusion Criteria\n\n* Age under 18 years.\n* Pregnancy or breastfeeding.\n* Preoperative treatment with anticoagulant or antiplatelet therapy that cannot be safely discontinued.\n* Known coagulation disorders or history of abnormal bleeding.\n* Known hypersensitivity or allergy to tranexamic acid.\n* History of seizure disorders or epilepsy.",{"count":47,"type":20},60,"INTERVENTIONAL",[50],"PHASE4","Tranexamic acid (TXA) is widely used in orthopedic surgery to reduce perioperative blood loss, particularly in total hip and knee arthroplasty, due to its antifibrinolytic mechanism, low cost, broad availability, and established safety profile. Its use has recently expanded to minimally invasive procedures such as knee arthroscopy and ACL reconstruction, where postoperative hemarthrosis-rather than intraoperative bleeding-is a major cause of pain, swelling, reduced range of motion, delayed rehabilitation, and impaired early recovery.\n\nRandomized trials and meta-analyses in arthroscopic ACL reconstruction show that TXA, administered intravenously, intra-articularly, or both, reduces postoperative hemarthrosis, joint swelling, drainage volume, and early pain, while improving early functional outcomes. These benefits are mainly short term, with no consistent long-term differences, and no increased risk of thromboembolic events. Evidence in arthroscopic meniscectomy is more limited but suggests modest improvements in early recovery, which may still be clinically meaningful given TXA's favorable risk-benefit profile.\n\nBeyond its antifibrinolytic effects, TXA may influence inflammatory pathways by inhibiting plasmin, which is involved in complement activation and inflammatory modulation. However, existing data are conflicting, with reports of both anti- and pro-inflammatory effects depending on surgical context and dosing. Importantly, most arthroscopy studies focus on clinical outcomes rather than systemic inflammation. To date, no study has comprehensively evaluated perioperative inflammatory responses to TXA in arthroscopic knee surgery, making this low-trauma setting an ideal model to investigate its potential inflammatory effects.",[53,54],"ACL Reconstruction","Hemarthrosis","2025-12-31",{"date":57,"type":29},"2026-01-12",{"date":59,"type":20},"2026-01-20",{"date":31,"type":20},{"name":35,"class":36},1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":48,"phases":76,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":62},"100576976","artificial-intelligence-assisted-colonoscopy-in-colorectal-cancer-screening-in-a-general-hospital-100576976","NCT06792292","Artificial Intelligence-Assisted Colonoscopy in Colorectal Cancer Screening in a General Hospital","Real-World Experience of Artificial Intelligence-Assisted Colonoscopy in Colorectal Cancer Screening in a General Hospital: A Single-Center Cohort Phase IV Study","Delta-AI","Inclusion criteria:\n\n* Patient (woman or man) candidate for a screening colonoscopy - Age: 45 to 74 years included\n* Absence of inflammatory bowel disease\n* Absence of significant digestive symptoms indicating colonoscopy (i.e. screening is the only indication for the examination)\n* Patient able to understand the concept of the study and agreeing to participate\n\nExclusion criteria:\n\n* Patient outside the inclusion age\n* All exclusion criteria for a colonoscopy.\n* The indication for colonoscopy is not simple screening; for example, assessment of anemia, rectal bleeding, weight loss or abdominal pain.\n* Patient's refusal to participate, or patient's inability to understand the study concept\n* Any patient with major psychological or psychiatric disorders.",true,"45 Years","74 Years",{"count":75,"type":20},765,[77],"NA","Cancer can develop in the colon, or large bowel. Examination of the colon with a tube fitted with a camera is called a colonoscopy.\n\nColonoscopy allows detection of small growths in the colon, called \"polyps\". Polyps can often be removed during colonoscopy. Some of these polyps are called adenomas and can become cancer after several years.\n\nA good colonoscopy aims to find and take out as many of these polyps as possible.\n\nA quality indication of colonoscopy is the \"adenoma detection rate\" (ADR). It should be high, meaning many polyps are detected and taken out.\n\nNew artificial intelligence devices to assist colonoscopy seem to increase the ADR, and maybe help prevent cancer even better than normal colonoscopy.\n\nThe goal of this clinical trial is to compare the ADR when using standard colonoscopy to the ADR with artificial intelligence (AI)-assisted colonoscopy.",[80,81,82,83,84],"Artificial Intelligence","Colonic Adenoma","Colonic Neoplasms","Colonic Polyp","Colonoscopy",[86,87],"colo-rectal cancer screening","artificial intelligence assisted colonoscopy","2025-01-20",{"date":90,"type":29},"2025-01-24",{"date":92,"type":20},"2025-02-01",{"date":94,"type":20},"2027-06-01",{"name":35,"class":36},""]